Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Trop Med Int Health. 2024 Jan;29(1):63-71. doi: 10.1111/tmi.13947. Epub 2023 Nov 20.
Isolated cases of subacute thyroiditis exist in the early period of COVID-19 vaccination, largely after mRNA vaccines. Here we report late onset thyroid disturbances and persistent health issues in patients of thyroid disorders after COVID-19 vaccination. Seventy-five patients with post COVID-19 vaccination thyroid disturbances were identified. Among these, 41 had flare of underlying thyroid illness, majority occurring at a median time lag of 28.4 weeks since 2nd dose. Thirty-one cases of new onset hypothyroidism and three of new onset hyperthyroidism were reported, with a median time lag respectively of 17.2 and 22.6 weeks since 2nd dose. Most cases occurred after ChAdOx1-nCoV-19, which was the commonest vaccine employed in mass roll out in India. Significant improvement was observed in majority, after a median follow up of 22-26 weeks. New onset health issues persisting for ≥4 weeks were reported in 37.3% and were common in individuals with history of COVID-19 before vaccine. New onset metabolic, musculoskeletal, and reproductive disorders were the common health complaints. Active monitoring is warranted for late onset adverse events after COVID-19 vaccines of all types. Larger studies with involvement of unvaccinated individuals are required to understand the incidence and causality of late onset thyroid disturbances after COVID-19 vaccines.
在 COVID-19 疫苗接种的早期,有孤立的亚急性甲状腺炎病例,主要发生在 mRNA 疫苗之后。在这里,我们报告 COVID-19 疫苗接种后甲状腺功能障碍患者的迟发性甲状腺紊乱和持续的健康问题。我们发现了 75 例接种 COVID-19 疫苗后甲状腺功能紊乱的患者。其中,41 例为潜在甲状腺疾病的发作,大多数发生在第二剂后中位数 28.4 周的时间滞后。报告了 31 例新发甲状腺功能减退症和 3 例新发甲状腺功能亢进症,第二剂后中位数时间滞后分别为 17.2 和 22.6 周。大多数病例发生在 ChAdOx1-nCoV-19 之后,这是印度大规模推广中最常用的疫苗。在中位数随访 22-26 周后,大多数病例观察到显著改善。37.3%的患者报告了持续≥4 周的新发健康问题,这些患者在疫苗接种前有 COVID-19 病史。新发的代谢、肌肉骨骼和生殖系统疾病是常见的健康问题。需要对所有类型的 COVID-19 疫苗进行主动监测,以了解迟发性不良事件的发生情况。需要更大规模的研究,包括未接种疫苗的个体,以了解 COVID-19 疫苗接种后迟发性甲状腺功能障碍的发生率和因果关系。